Audrey Vachon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Audrey Vachon has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Porlier
Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval (CRIUCPQ-ULaval), 2725, Chemin Sainte-Foy, Quebec City, QC G1V 4G5, Canada
1 shared publication - Benoit Drolet
Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval (CRIUCPQ-ULaval), 2725, Chemin Sainte-Foy, Quebec City, QC G1V 4G5, Canada
1 shared publication - Chantale Simard
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada
1 shared publication Frédéric Picard
Centre de Recherche de l’Hôpital Laval
1 shared publication- Isabelle Cloutier
Faculté de Pharmacie, Université Laval, 1050, Avenue de la Médecine, Local 2345, Quebec City, QC G1V 0A6, Canada
1 shared publication Marie-David Simoneau
Hôpital de l'Enfant-Jésus, Centre Hospitalier Affilié Universitaire de Québec, Quebec City, QC, Canada
1 shared publication
Latest Publications
- Open Access
Stability of Injectable Ceftobiprole Medocaril (Zevtera®) in PVC Bags and in the Intermate® Infusion System: A Technological Turning Point for Ambulatory Administration of Intravenous Antibiotics
Background: Ceftobiprole medocaril (Zevtera®) is an injectable broad-spectrum antibiotic. Objective: We aim to show that ceftobiprole initiated in hospital may be continued at home through Outpatient Parenteral Antibiotic Therapy (OPAT). Methods: Solutions of ceftobiprole at 2.0 and 2.8 mg/mL were prepared in PVC bags from 500 mg vials and stored at room temperature (RT) or 4 °C. Each sample was analyzed in triplicate samples using high-performance liquid chromatography (HPLC) at multiple time points over a 120 h period. Additionally, 2.5 mg/mL ceftobiprole solutions were prepared in Intermate® infusion devices (n = 3 preparations) and stored at 4 °C. Samples were collected on multiple days from Day 0 to Day 9, both immediately post-refrigeration and after 8 h at RT and analyzed in triplicate. Results: PVC bag solutions retained ≥90% of their initial concentrations. At RT, residual concentration was 90.9% (2.0 mg/mL) and 92.0% (2.8 mg/mL) after 24 h. At 4 °C, the 2.0 mg/mL formulation retained 90.8% after 120 h, and the 2.8 mg/mL formulation retained 90.2% after 96 h. Intermate® devices stored nine days at 4 °C and exposed to RT for 8 h retained ≥90% of the initial concentration of ceftobiprole (2.5 mg/mL; 93.3% before RT exposure; 91.1% after). Conclusions: Ceftobiprole medocaril exhibits sufficient physicochemical stability for OPAT use in PVC bags and Intermate® infusion device under tested conditions.
Open AccessStability of Injectable Ceftobiprole Medocaril (Zevtera®) in PVC Bags and in the Intermate® Infusion System: A Technological Turning Point for Ambulatory Administration of Intravenous Antibiotics
Background: Ceftobiprole medocaril (Zevtera®) is an injectable broad-spectrum antibiotic. Objective: We aim to show that ceftobiprole initiated in hospital may be continued at home through Outpatient Parenteral Antibiotic Therapy (OPAT). Methods: Solutions of ceftobiprole at 2.0 and 2.8 mg/mL were prepared in PVC bags from 500 mg vials and stored at room temperature (RT) or 4 °C. Each sample was analyzed in triplicate samples using high-performance liquid chromatography (HPLC) at multiple time points over a 120 h period. Additionally, 2.5 mg/mL ceftobiprole solutions were prepared in Intermate® infusion devices (n = 3 preparations) and stored at 4 °C. Samples were collected on multiple days from Day 0 to Day 9, both immediately post-refrigeration and after 8 h at RT and analyzed in triplicate. Results: PVC bag solutions retained ≥90% of their initial concentrations. At RT, residual concentration was 90.9% (2.0 mg/mL) and 92.0% (2.8 mg/mL) after 24 h. At 4 °C, the 2.0 mg/mL formulation retained 90.8% after 120 h, and the 2.8 mg/mL formulation retained 90.2% after 96 h. Intermate® devices stored nine days at 4 °C and exposed to RT for 8 h retained ≥90% of the initial concentration of ceftobiprole (2.5 mg/mL; 93.3% before RT exposure; 91.1% after). Conclusions: Ceftobiprole medocaril exhibits sufficient physicochemical stability for OPAT use in PVC bags and Intermate® infusion device under tested conditions.
- 18 October 2008
- Published by Springer Nature in Obesity Surgery
- Vol. 20 (4) , 487-491
Effect of Prophylactic Dalteparin on Anti-factor Xa Levels in Morbidly Obese Patients After Bariatric Surgery
There are limited data on appropriate dosing of low-molecular-weight heparins (LMWH) for venous thromboembolism (VTE) prophylaxis in bariatric surgery. The objective of this study was to describe the postoperative effects of LMWH dalteparin on anti-factor Xa (AFXa) level in morbidly obese patients undergoing bariatric surgery.
- 18 October 2008
- Published by Springer Nature in Obesity Surgery
- Vol. 20 (4) , 487-491
Effect of Prophylactic Dalteparin on Anti-factor Xa Levels in Morbidly Obese Patients After Bariatric Surgery
There are limited data on appropriate dosing of low-molecular-weight heparins (LMWH) for venous thromboembolism (VTE) prophylaxis in bariatric surgery. The objective of this study was to describe the postoperative effects of LMWH dalteparin on anti-factor Xa (AFXa) level in morbidly obese patients undergoing bariatric surgery.